文献速递神经肿瘤

新型DNA交联剂KL-50对替莫唑胺治疗后新发和复发错配修复缺陷胶质母细胞瘤患者来源模型具有活性

The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.
PubMed 文献 · Neuro Oncol · 2025-01-01

该研究在患者来源的错配修复缺陷胶质母细胞瘤异种移植模型中测试新型DNA交联剂KL-50。KL-50延长了新发和替莫唑胺治疗后复发肿瘤小鼠的中位生存期,且MSH6敲除反而降低KL-50的IC50。KL-50类药物可能是治疗MGMT缺陷、MMR缺陷且一线替莫唑胺后复发胶质母细胞瘤的新策略。

要点

  • KL-50使新发GBM6和GBM12小鼠中位生存期分别延长1.75倍和2.15倍,P<0.0001。
  • 低剂量分次放疗(4 Gy)进一步延长KL-50治疗的GBM12小鼠生存期,中位80天对71天,P=0.018。
  • MSH6敲除使TMZ的IC50升高,但KL-50的IC50反而降低10-80%。

核心结论

  • KL-50类药物是治疗MGMT缺陷、MMR缺陷且一线替莫唑胺后复发胶质母细胞瘤的有前景的新策略。

研究设计与样本

  • 通过替莫唑胺暴露创建MMR缺陷的胶质母细胞瘤患者来源异种移植模型,随后用替莫唑胺或KL-50治疗。
  • 生成同基因MSH6敲除的患者来源胶质母细胞瘤,并检测其对替莫唑胺和KL-50的敏感性。

主要发现

  • KL-50使颅内移植新发GBM6或GBM12的小鼠中位生存期分别延长1.75倍和2.15倍(P<0.0001)。
  • 低剂量(4 Gy)分次放疗进一步延长KL-50治疗的GBM12小鼠生存期(中位生存期:放疗+KL-50为80天 vs KL-50单药为71天,P=0.018)。
  • KL-50延长了移植替莫唑胺后MMR缺陷GBM6R-m185的小鼠中位生存期(KL-50为140天 vs 溶媒为37天,P<0.0001)。
  • MSH6敲除使GBM6和GBM12培养的替莫唑胺IC50分别升高>5倍和>12倍(分别对应细胞死亡和活细胞计数输出)。
  • 相反,MSH6敲除使KL-50的IC50降低10-80%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acquired resistance to temozolomide (TMZ) chemotherapy due to DNA mismatch repair (MMR) enzyme deficiency is a barrier to improving outcomes for isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients. KL-50 is a new imidazotetrazine-based therapeutic designed to induce DNA interstrand cross-links, and subsequent double-stranded breaks, in an MMR-independent manner in cells with O-6-methylguanine-DNA methyltransferase (MGMT) deficiency. Previous research showed its efficacy against LN229 glioma cells with MMR and MGMT knockdown. Its activity against patient-derived GBM that model post-TMZ recurrent tumors is unclear. METHODS: We created MMR-deficient GBM patient-derived xenografts through exposure to TMZ, followed by treatment with additional TMZ or KL-50. We also generated isogenic, MSH6 knockout (KO) patient-derived GBM and tested them for sensitivity to TMZ and KL-50. RESULTS: KL-50 extended the median survival of mice intracranially engrafted with either patient-derived TMZ-naïve GBM6 or TMZ-naïve GBM12 by 1.75-fold and 2.15-fold, respectively (P < 0.0001). A low dose (4 Gy) of fractionated RT further extended the survival of KL-50-treated GBM12 mice (median survival = 80 days for RT + KL-50 vs. 71 days KL-50 alone, P = 0.018). KL-50 also extended the median survival of mice engrafted with post-TMZ, MMR-deficient GBM6R-m185 (140 days for KL-50 vs. 37 days for vehicle, P < 0.0001). MSH6 KO increased TMZ IC50 for GBM6 and GBM12 cultures by >5-fold and >12-fold for cell death and live cell count outputs, respectively. In contrast, MSH6-KO actually decreased KL-50 IC50 by 10-80%. CONCLUSION: KL-50-based compounds are a promising new strategy for the treatment of MGMT-deficient, MMR-deficient GBM that recurs after frontline TMZ.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. McCord M, Sears T, Wang W, et al. The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro Oncol. 2025. PMID: 39658092. doi:10.1093/neuonc/noae257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。